Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMEX 
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
Recursion Pharmaceuticals (RXRX) closed at $4.65 in the latest trading session, marking a -4.12% move from the prior day.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
What's Happening With RXRX Stock?
Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However, here's a reality check: RXRX remains down by 35% year-to-date and is trading below $5.
Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Recursion Pharmaceuticals, Inc. ( RXRX ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:30 AM EST Company Participants Christopher Gibson - Co-Founder, CEO & Director Najat Khan - Chief R&D Officer, Chief Commercial Officer and Director Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Good morning. Welcome to the Jefferies London Healthcare Conference.
Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?
Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating losses, and significant share dilution, with profitability likely several years away despite strong partnerships and a robust balance sheet. RXRX stock trades at a steep valuation premium, and meaningful revenue from internal drug candidates is not expected until at least 2027.
RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y
Recursion Pharmaceuticals narrows its Q3 loss but posts lower-than-expected revenues due to reduced collaboration revenues from its partners.
Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript
Recursion Pharmaceuticals, Inc. ( RXRX ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Christopher Gibson - Co-Founder, CEO & Director Najat Khan - Chief R&D Officer, Chief Commercial Officer and Director Ben Taylor - CFO & President of Recursion UK Presentation Christopher Gibson Co-Founder, CEO & Director " Najat Khan Chief R&D Officer, Chief Commercial Officer and Director " Ben Taylor CFO & President of Recursion UK " Christopher Gibson Co-Founder, CEO & Director Hello, everybody, and welcome to Recursion's Third Quarter 2025 (L)earnings Call. My name is Chris Gibson.
Earnings Preview: Recursion Pharmaceuticals (RXRX) Q3 Earnings Expected to Decline
Recursion Pharmaceuticals (RXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $5.91, indicating a -6.19% shift from the previous trading day.
Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $6.36, moving 6.33% from the previous trading session.
